Navigation Links
InNexus Completes Previously Announced Private Placement
Date:1/27/2009

BRITISH COLUMBIA, Canada, Jan. 27 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), announced today that it has completed a second private placement on the same terms and conditions as the private placement that was completed 12 December 2008.

The private placement, totaled $2,207,000 of 10% unsecured convertible debentures. Each Debenture will be convertible into common shares of InNexus at the rate of one common share for each $0.10 of debt converted. The Debenture will have a term of 2 years. In the course of this private placement, InNexus has redeemed $624,000 in value of preferred shares which was reinvested by the holder of such redeemed preferred shares in the Debenture. Net proceeds from the private placement which is approximately $911,000 will be used by InNexus for research and development and general corporate business.

In connection with the private placement, certain insiders of InNexus comprised of the Chairman & CEO, some members of the Board and senior management, participated on the same terms in the offering for an aggregate of approximately 19% of the issued Debenture. InNexus paid a $7,000 finders' fee or 7% of the proceeds was paid to an investment company from the sale of the Debentures to purchasers referred by such finder in accordance with the policies of the TSX Venture Exchange.

Participation in the private placement by insiders of InNexus is considered to be a related-party transaction as defined under Multilateral Instrument 61-101. The transaction is, however, exempt from the formal valuation and minority shareholder approval requirements under the Instrument as neither the fair market value of the securities being issued nor the consideration paid exceeds 25 percent of InNexus' market capitalization.

Upon conversion of the Debenture,
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
2. InNexus Biotechnology Receives Patent Grants in Europe
3. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
4. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
5. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
6. InNexus Biotechnology Strengthens Patent Team With New Leadership
7. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
8. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
9. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
10. DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
11. Mach One Completes Note Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
(Date:1/14/2014)... 14, 2014 During the 1600’s through the ... “The Doctor’s Plague.” In this time period, doctors did not ... at times, to the death of vulnerable patients. In the ... that they may be unwittingly transmitting herpes viruses to their ...
(Date:1/14/2014)... Holloway America today announced an addition ... reports (MTRs) for all pressure vessels and tank parts ... particularly important for equipment that must meet ASME, CE, ... search functionality that allows authorized users to quickly locate ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... Cephalon, Inc. (NASDAQ: CEPH ) today ... Statement with the Securities and Exchange Commission (SEC) urging ... remove Cephalon,s entire Board of Directors and replace them ... of the Statement to shareholders of record together with ...
... NEW YORK, April 21, 2011 Collins Stewart LLC ... healthcare investment banking alliance with Beal Advisors and Liberty ... target, originate and execute public and private equity transactions ... Tree Advisors are US-based boutique healthcare advisory firms. Georgia ...
... 21, 2011 The Stanford University School of ... of a Phase 1/2a clinical trial testing the ... therapy product, SB623, on patients suffering from stable ... regarding this clinical trial, please refer to the ...
Cached Biology Technology:Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 2Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 3Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 4Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 5Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 6Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 7Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 8Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 9Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 10Collins Stewart Announces Formation of Healthcare Investment Banking Alliance 2Collins Stewart Announces Formation of Healthcare Investment Banking Alliance 3Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability 2
(Date:4/20/2014)... crop residue to make ethanol and other biofuels reduces ... gasoline, according to a study published today in the ... by a University of Nebraska-Lincoln team of researchers cast ... meet federal mandates to ramp up ethanol production and ... stalks, leaves and cobs in cornfields after harvest -- ...
(Date:4/18/2014)... adds a twist to the story of how barnyard chickens ... 21 in the journal Proceedings of the National Academy ... chickens that lived 200-2300 years ago in Europe, researchers report ... have looked far different from the chickens we know today. ... associate with modern domestic chickens -- such as their yellowish ...
(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Ancient DNA offers clues to how barnyard chickens came to be 2Multitarget TB drug could treat other diseases, evade resistance 2
... origins of holiday giving and finds that our early ... arguably the foundational basis of cooperation in humans," writes ... feature of reciprocity is the contingent relationship between acts ... important because it sets the rules for who qualifies ...
... the United States could be grown inexpensively and safely ... of Central Florida molecular biologist has found. , Mice ... Daniell's laboratory through the genetic engineering of tobacco plants ... Institutes of Health researchers. The results of the NIH-funded ...
... -- a critical protein that mediates the body's defense against ... soon have greater therapeutic value as the result of a ... in St. Louis. , "Essentially, we found a way ... Michael J. Holtzman, M.D., the Selma and Herman Seldin Professor ...
Cached Biology News:Effective, safe anthrax vaccine can be grown in tobacco plants 2Effective, safe anthrax vaccine can be grown in tobacco plants 3Greasing interferon's gears may pave way to greater therapeutic benefits, fewer side effects 2
CQCS kit for first KR 4i , (first unit)....
... 384, compatible with hood ... handling system for 384-well ... accurately prepares large quantities ... The Wellpro also performs ...
...
...
Biology Products: